| COVID-19 | Coronavirus disease-2019 |
| CPT | Convalescent plasma therapy |
| FDA | Food and Drug Administration |
| IFNs | Interferons |
| IFN-I | IFN type 1 |
| IFN-α | Interferon alpha |
| IFN-α-2b | Interferon-alpha-2b |
| IFN-β | Interferon beta |
| IFN-β-1a | Interferon-beta-1a |
| IL-6 | Interleukin-6 |
| JAK | Janus kinase |
| MSCs | Mesenchymal stem cells |
| PaO2/FiO2 | Partial arterial oxygen pressure to the fraction of inspiration O2 |
| RECOVERY | Randomized Evaluation of COVID-19 Therapy |
| REMAP-CAP | The Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia |
| RdRp | RNA-dependent polymerase |
| SARS-CoV | A severe acute respiratory coronavirus infection |
| SARS-CoV-2 | A severe acute respiratory coronavirus infection-2 which is a Coronavirus disease-2019 |
| VEGF | Anti-vascular endothelial growth factor |
| WHO | World Health Organization |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.